BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 38470973)

  • 41. Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study.
    Musto P; Simeon V; Grossi A; Gay F; Bringhen S; Larocca A; Guariglia R; Pietrantuono G; Villani O; D'Arena G; Cuomo C; Musto C; Morabito F; Petrucci MT; Offidani M; Zamagni E; Tacchetti P; Conticello C; Milone G; Palumbo A; Cavo M; Boccadoro M
    Stem Cell Res Ther; 2015 Apr; 6(1):64. PubMed ID: 25889496
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.
    Sánchez-Ortega I; Querol S; Encuentra M; Ortega S; Serra A; Sanchez-Villegas JM; Grifols JR; Pujol-Balaguer MM; Pujol-Bosch M; Martí JM; Garcia-Cerecedo T; Barba P; Sancho JM; Esquirol A; Sierra J; Duarte RF
    Bone Marrow Transplant; 2015 Jan; 50(1):34-9. PubMed ID: 25222503
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilization.
    Rossi G; Skert C; Morello E; Almici C; Arcaini L; Basilico C; Cavalli L; Botto B; Castelli A; Pica G; Ripamonti F; Salvi F; Carella AM; Gaidano G; Levis A; Nosari A; Russo D; Vitolo U
    Hematol Oncol; 2015 Sep; 33(3):125-32. PubMed ID: 24890497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. G-CSF: filgrastim, lenograstim and biosimilars.
    Welte K
    Expert Opin Biol Ther; 2014 Jul; 14(7):983-93. PubMed ID: 24707817
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation.
    Schmitt M; Publicover A; Orchard KH; Görlach M; Wang L; Schmitt A; Mani J; Tsirigotis P; Kuriakose R; Nagler A
    Theranostics; 2014; 4(3):280-9. PubMed ID: 24505236
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.
    Micallef IN; Stiff PJ; Stadtmauer EA; Bolwell BJ; Nademanee AP; Maziarz RT; Partisano AM; Marulkar S; DiPersio JF
    Am J Hematol; 2013 Dec; 88(12):1017-23. PubMed ID: 23907769
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.
    Maziarz RT; Nademanee AP; Micallef IN; Stiff PJ; Calandra G; Angell J; Dipersio JF; Bolwell BJ
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):670-5. PubMed ID: 23333777
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.
    Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
    Transfus Apher Sci; 2012 Jun; 46(3):257-62. PubMed ID: 22465758
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration.
    Horwitz ME; Chute JP; Gasparetto C; Long GD; McDonald C; Morris A; Rizzieri DA; Sullivan KM; Chao NJ
    Bone Marrow Transplant; 2012 Aug; 47(8):1051-5. PubMed ID: 22080963
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.
    Andreola G; Babic A; Rabascio C; Negri M; Martinelli G; Laszlo D
    Eur J Haematol; 2012 Feb; 88(2):154-8. PubMed ID: 21992403
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.
    Keating GM
    Drugs; 2011 Aug; 71(12):1623-47. PubMed ID: 21861545
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution.
    Cooper DL; Pratt K; Baker J; Medoff E; Conkling-Walsh A; Foss F; Snyder E; Yen W; Seropian SE
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):267-72. PubMed ID: 21658654
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High cytogenetic or molecular genetic risk acute myeloid leukemia.
    Estey E
    Hematology Am Soc Hematol Educ Program; 2010; 2010():474-80. PubMed ID: 21239839
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation.
    Mohty M; Duarte RF; Croockewit S; Hübel K; Kvalheim G; Russell N
    Leukemia; 2011 Jan; 25(1):1-6. PubMed ID: 21224858
    [No Abstract]   [Full Text] [Related]  

  • 55. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells.
    Boitano AE; Wang J; Romeo R; Bouchez LC; Parker AE; Sutton SE; Walker JR; Flaveny CA; Perdew GH; Denison MS; Schultz PG; Cooke MP
    Science; 2010 Sep; 329(5997):1345-8. PubMed ID: 20688981
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.
    DiPersio JF; Micallef IN; Stiff PJ; Bolwell BJ; Maziarz RT; Jacobsen E; Nademanee A; McCarty J; Bridger G; Calandra G;
    J Clin Oncol; 2009 Oct; 27(28):4767-73. PubMed ID: 19720922
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.
    DiPersio JF; Stadtmauer EA; Nademanee A; Micallef IN; Stiff PJ; Kaufman JL; Maziarz RT; Hosing C; Früehauf S; Horwitz M; Cooper D; Bridger G; Calandra G;
    Blood; 2009 Jun; 113(23):5720-6. PubMed ID: 19363221
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clustering of cancer among families of cases with Hodgkin Lymphoma (HL), Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), Soft Tissue Sarcoma (STS) and control subjects.
    McDuffie HH; Pahwa P; Karunanayake CP; Spinelli JJ; Dosman JA
    BMC Cancer; 2009 Feb; 9():70. PubMed ID: 19250521
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
    Stiff P; Micallef I; McCarthy P; Magalhaes-Silverman M; Weisdorf D; Territo M; Badel K; Calandra G
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):249-56. PubMed ID: 19167685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.